Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Label Update for Cosentyx

Novartis news release; 2018 Feb 8

Novartis has announced that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis. Approximately half of all 125 million people with psoriasis suffer from scalp psoriasis, which can have an impact on patients' quality of life.

Indications: The updated label includes Cosentyx data in moderate-to-severe scalp psoriasis—one of the difficult-to-treat forms of the disease. Scalp psoriasis can be challenging to treat with topical agents or phototherapy due to the presence of hair and other factors. The update is effective in the US immediately, and is based on the proven efficacy and consistent safety profile of Cosentyx from a dedicated Phase III scalp psoriasis trial.

Dosage/administration: Recommended dosage for plaque psoriasis is 300 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. For some patients, a dose of 150 mg may be acceptable.

Adverse effects: Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.


Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis. [news release]. Basel, Switzerland: Novartis. February 8, 2018. Accessed February 12, 2018.

This Week's Must Reads

Should Medical Coding Be Taught During Residency?, J Drugs Dermatol; 2018 Jun; Blecher, Halverstam, et al

Primary Closure Lengths in MMS Based on Cancer Type, Dermatolog Surg; ePub 2018 Jun 8; Theroux, et al

Citizen Pscientist: Important New Research Tool, Dermatol Ther (Heidelb); ePub 2018 Jun 6; Sanchez, et al

Acne Successfully Treated with Laser Combination, Dermatolog Surg; ePub 2018 Jun 5; Bakus, et al

FDA Approves Rituxan for Pemphigus Vulgaris, Genentech Web site; 2018 Jun 7

Must Reads in FDA Actions

FDA Approves Rituxan for Pemphigus Vulgaris, Genentech Web site; 2018 Jun 7

FDA Extends Label for Cimzia for Plaque Psoriasis, UCB news release; 2018 May 29

FDA Updates Label for Taltz for Genital Psoriasis, PharmaLive news release; 2018 May 22

FDA Approves Restylane Lyft for Back of Hands, FirstWord Pharma news release; 2018 May 21

FDA Approves Tafinlar-Mekinist Combo for Melanoma, Novartis news release; 2018 Apr 30